NCT06651970 2026-02-23
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
AstraZeneca
Phase 4 Recruiting
AstraZeneca
AstraZeneca
AbbVie
University of Birmingham
Gilead Sciences
European Institute of Oncology
Ohio State University Comprehensive Cancer Center
Celgene Corporation
Vilnius University